Success Story: Targeting Pancreatic Cancer Through Genetics Research: I-140 NIW Approval Secured for a Researcher from Oman
Client’s Testimonial:
"Thank you very much for all of your help and support throughout my NIW process. I truly appreciate your team’s efforts and guidance.”
On June 4th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Fellow in the field of Genetics (Approval Notice).
General Field: Genetics
Position at the Time of Case Filing: Postdoctoral Fellow
Country of Origin: Oman
State of Residence at the Time of Filing: New York
Approval Notice Date: June 4th, 2026
Processing Time: 1 year, 6 months, 14 days (Premium Processing Requested)
Case Summary:
Pancreatic cancer remains one of the most aggressive cancer types, and progress depends on identifying the genetic mechanisms that allow tumor cells to grow, adapt, and resist treatment. For this genetics researcher from Oman, the proposed endeavor focused on investigating how transcription factors regulate the basal phenotype of pancreatic ductal adenocarcinoma in order to identify new therapeutic targets for more effective cancer treatment. At the time of filing, the client was conducting research at a U.S. research institution, where she continued work involving cancer genetics, epigenetics, computational analysis, gene-editing technologies, patient-derived organoids, and sequencing-based methods to study pancreatic cancer biology.
Research Contributions in Genetics
The client’s research bridges cancer genetics, epigenetic regulation, and therapeutic development. Her ongoing work focuses on uncovering genetic and epigenetic drivers of pancreatic cancer and evaluating how specific molecular pathways may be targeted for treatment. Her broader research record also includes work on advanced drug delivery systems, nanoparticle-based cancer therapy, and cellular mechanisms relevant to tumor biology. Together, these contributions support the development of more precise approaches to cancer treatment and disease modeling.
Academic Contributions and Recognition
The client’s record included 4 peer-reviewed journal articles, 2 first-authored conference abstracts, and 484 citations. Her research appeared in respected journals in genetics, molecular biology, pharmaceutical sciences, drug delivery, and cancer-related research. Several of her publications ranked among the most cited Molecular Biology and Genetics papers for their publication years, including one paper ranked within the top 1%, two papers ranked within the top 10%, and one paper ranked within the top 20%.
The petition demonstrated the significance of the client’s work through her publication record, citation impact, highly ranked publication venues, bibliometric evidence, and documented reliance on her findings by independent researchers. Other scholars had used her work in studies involving nanoparticle drug delivery, targeted cancer therapy, inhaled treatment systems, and strategies for improving drug retention and delivery to diseased tissues.
NIW Approval and Outlook
The I-140 NIW petition was filed on November 21st, 2024, later upgraded to Premium Processing, and approved on June 4th, 2026. The approval recognized the importance of the client’s genetics research and its connection to the development of more effective therapeutic strategies for pancreatic cancer.
This outcome allows the client to continue pursuing research that may help clarify pancreatic cancer biology, identify new treatment targets, and contribute to future advances in genetics-based cancer therapy in the United States.